CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analogue studied for its effect on growth hormone secretion. The "with DAC" version is modified for a longer half-life, while the "no DAC" version (sometimes called Mod GRF 1-29) clears the body faster and is typically researched alongside a GHRP such as Ipamorelin.
With DAC vs. without DAC
"CJC-1295" is sold in two distinct forms with very different pharmacokinetics. With DAC ("Drug Affinity Complex") covalently binds circulating albumin, protecting it from renal clearance — half-life ~5.8-8.1 days. Without DAC (also labeled "Mod GRF 1-29") lacks that linker — half-life ~30 minutes. The human trial below used the with-DAC form.
Benefits
CJC-1295 is a GHRH (growth-hormone-releasing hormone) analog — it stimulates the pituitary's own GH production rather than supplying GH directly.
Human RCT (with-DAC): a single subcutaneous dose produced dose-dependent GH increases of 2-10 fold sustained for 6+ days, and IGF-1 increases of 1.5-3 fold sustained for 9-11 days. Repeated weekly/biweekly dosing over 49 days kept IGF-1 above baseline for up to 28 days, with a cumulative effect across doses. Teichman et al., J Clin Endocrinol Metab, 2006
This is a real, placebo-controlled, dose-ranging human trial — meaningfully stronger human evidence than most compounds in this category.
Dosage
With-DAC (human trial): single ascending subcutaneous doses of 30, 60, or 90μg/kg were tested; tolerability was best at 30-60μg/kg. Repeat dosing used weekly or biweekly subcutaneous injections over 49 days.
Without-DAC: no equivalent human dosing trial found. Community-use conventions (smaller, more frequent doses timed around meals/sleep) are widely discussed but not verified against a clinical source.
Reconstitution
Standard reconstitution math applies — the with-DAC and without-DAC forms are typically sold in different vial sizes given their different dosing patterns (less-frequent larger doses vs. more-frequent smaller doses).
Side Effects
In the one real human trial (with-DAC): "no serious adverse reactions were reported" across both single-dose and repeat-dose phases, with best tolerability at 30-60μg/kg. No dedicated safety trial found for the without-DAC form — its safety profile shouldn't be assumed to be identical just because the sequences are related.
Results Timeline
Directly sourced to human data, not animal extrapolation: single dose (with-DAC) — GH elevated 6+ days, IGF-1 elevated 9-11 days. Repeated dosing — IGF-1 sustained above baseline for up to 28 days. No equivalent timeline data exists for the without-DAC form, whose much shorter half-life means its effect is really about acute GH-pulse timing around each dose rather than a multi-day pattern.
What is the difference between CJC-1295 with DAC and without DAC?+
With DAC is modified for an extended half-life of several days; without DAC (Mod GRF 1-29) has a short half-life of minutes and is generally paired with a growth-hormone-releasing peptide.
Is CJC-1295 legal?+
It is not FDA-approved for human use and is commonly sold labeled research use only. It is prohibited under WADA as a growth-hormone-releasing factor (S2.2).
What is CJC-1295 usually stacked with?+
It is most commonly discussed alongside Ipamorelin in research contexts, since the two are proposed to act on complementary growth-hormone-release pathways.
What is it?+
GHRH analog, the long-acting backbone most GH stacks are built around.
What are its side effects?+
Mild hunger, water retention, tingling, or redness. Usually fixed by lowering dose/rotating sites.
Why take CJC-1295 before sleep?+
Your body does most of its growth hormone work while you're asleep — roughly 70% of daily GH release happens overnight, concentrated in that first deep-sleep stretch within about 90 minutes of falling asleep. Cut that sleep short or make it restless, and you cut that pulse short too.
What makes CJC-1295 specifically worth timing around bedtime: GHRH doesn't just trigger GH release, it also helps you sleep more deeply in its own right — research shows it extends slow-wave sleep and cuts down on waking during the night, independent of whatever GH effect follows. Dosing before bed is really just lining the peptide up with a pulse your body was already going to try to produce anyway.
With-DAC vs without-DAC — what's the real difference?+
Both are still CJC-1295 mimicking your body's own GHRH pulses — neither is the same as taking direct HGH, which skips your pituitary entirely and floods your system continuously.
With DAC: a long half-life (days), giving one big sustained GH signal that can flatten into fewer real pulses over time and risks desensitizing receptors with prolonged use.
Without DAC (Mod GRF 1-29): a short half-life (minutes to hours), producing multiple natural-style pulses through the day — closer to how your body actually secretes GH, with less receptor burnout.
That's why CJC-1295 No-DAC + Ipamorelin is generally considered the more sustainable long-term combination.
Can it help me grow?+
Yes, indirectly. More GH means higher IGF-1, which supports better recovery, nutrient partitioning, fat loss, and lean muscle gain.
How to amplify results+
It doesn't replace training, diet, or sleep — it amplifies them. The peptide only has raw material to work with if those fundamentals are in place.
Does it lose effectiveness over time (desensitization)?+
Not a permanent burnout, but yes — running any of them continuously without a break can lead to your pituitary responding less over time.
The mechanism: repeated stimulation causes GHRH receptors to get pulled inside the cell rather than staying on the surface ready to respond — a normal cellular process, not unique to peptides, but it means fewer active receptors the longer you go without a break.
Short-acting vs. long-acting matters here. Sermorelin and Tesamorelin clear your system in minutes, giving the receptor real recovery time between each pulse. CJC-1295 with DAC works differently: it binds to albumin and stays active for days, keeping the receptor engaged almost continuously instead of in pulses, which is the higher-risk setup for gradual desensitization.
That's the real reasoning behind cycling — running a GHRH analog for a stretch (commonly cited: roughly 8-12 weeks), then a few weeks off, specifically to let receptors recover before starting again.
Is stacking two GHRH analogs (e.g. CJC-1295 and Tesamorelin) worth it?+
Generally not, and yes — genuinely redundant. Two GHRH analogs taken together are both aiming at the exact same receptor on your pituitary. Rather than adding up, they end up competing for the same doorway — one doesn't multiply what the other's doing.
Real synergy needs two different mechanisms working at once, which is exactly why the GHRH + GHRP pairing (CJC-1295 with Ipamorelin, say) is the combination that actually gets cited — one preps the supply, the other triggers the release, hitting different levers instead of the same one twice.
Stacking two GHRH analogs instead mostly means paying for two products doing one job, no real gain in GH output, and a higher total peptide load with a somewhat higher chance of side effects like water retention or joint stiffness that scale with dose rather than results.
Looking for something specific, or placing a wholesale order? Send us a DM or email.